Gilbert Gottfried had myotonic dystrophy before his death. What is the rare disease? Comedian Gilbert Gottfried died on Tuesday after a long illness, his family announced. Tribune News Service · Apr 13, 2022
Q&A: Penn ethicist Zeke Emanuel has another life as a venture capitalist Ezekiel Emanuel chairs the department of medical ethics and health policy at the University of Pennsylvania. He started the bioethics department at the National Institutes of Health, helped shape U.S. health-care policy as a senior aide in the Obama administration, served on President Joe Biden's COVID-19 task force, and advocates… The Philadelphia Inquirer · Apr 13, 2022
Repurposing generic drugs can reduce time and cost to develop new treatments – but low profitability remains a barrier Discovering new ways to use existing drugs can come about intentionally or by chance. The Conversation · Apr 6, 2022
New data-sharing requirements from the National Institutes of Health are a big step toward more open science – and potentially higher-quality research Starting on Jan. 25, 2023, many of the 2,500 institutions and 300,000 researchers that the U.S. National Institutes of Health supports will need to provide a formal, detailed plan for publicly sharing the data generated by their research. For many in the scientific community, this new NIH Data Management and… The Conversation · Mar 24, 2022
COVID’s ‘silver lining’: Research breakthroughs for chronic disease, cancer and the common flu The billions of dollars invested in COVID vaccines and COVID-19 research so far are expected to yield medical and scientific dividends for decades, helping doctors battle influenza, cancer, cystic fibrosis and far more diseases. Tribune News Service · Mar 21, 2022
Moderna Moves Forward With Second HIV Vaccine Trial Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble… Benzinga · Mar 14, 2022
NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185 SAB Biotherapeutics Inc (NASDAQ:SABS) said that due to low hospitalization and death rates in the trial, the National Institutes of Health's (NIH) ACTIV-2 Program is discontinuing enrollment in its Phase 3 COVID-19 trial. SAB-185 was being assessed as part of Phase 3 ACTIV-2 master protocol evaluating treatments for COVID-19 in patients with… Benzinga · Mar 2, 2022
Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted? Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health. Los Angeles Times · Feb 10, 2022
Mayo Clinic Minute: How COVID-19 has affected cancer care Cancer has not rested during the COVID-19 pandemic, as is evident by the number of people diagnosed with cancer since 2020. Research published by the National Institutes of Health suggests that delayed screening during the pandemic has led to thousands of deaths and make cancers more difficult to treat when… Tribune News Service · Feb 4, 2022
BHU scientists bring a ray of hope in Diabetic foot ulcer treatment Scientists from the Banaras Hindu University (BHU) have found a cure for chronic wounds, particularly diabetic foot ulcers. The research findings have been published in the National Centre for Biotechnology Information (NCBI), National Institutes of Health (NIH), US. The Times of India · Jan 19, 2022